One of Lundbeck’s key pipeline drugs, Idalopirdine, for the treatment of Alzheimer’s disease (being developed in collaboration with Otsuka) flunked in a phase III study called STARSHINE. The drug failed to meet both primary and secondary end-points in either of the two doses, sending the shares down by c.15% on last Friday (23 September 2016). This was the first of the three phase III trials (data from the remaining trials is expected in Q1 17). The news had a ripple effect on Axo
26 Sep 2016
Another Alzheimer's drug bites the dust
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Another Alzheimer's drug bites the dust
One of Lundbeck’s key pipeline drugs, Idalopirdine, for the treatment of Alzheimer’s disease (being developed in collaboration with Otsuka) flunked in a phase III study called STARSHINE. The drug failed to meet both primary and secondary end-points in either of the two doses, sending the shares down by c.15% on last Friday (23 September 2016). This was the first of the three phase III trials (data from the remaining trials is expected in Q1 17). The news had a ripple effect on Axo